CO5180628A1 - CALCIOLITIC COMPOUNDS - Google Patents

CALCIOLITIC COMPOUNDS

Info

Publication number
CO5180628A1
CO5180628A1 CO00056902A CO00056902A CO5180628A1 CO 5180628 A1 CO5180628 A1 CO 5180628A1 CO 00056902 A CO00056902 A CO 00056902A CO 00056902 A CO00056902 A CO 00056902A CO 5180628 A1 CO5180628 A1 CO 5180628A1
Authority
CO
Colombia
Prior art keywords
amino
hydroxy
phenoxy
cyano
dimethyl
Prior art date
Application number
CO00056902A
Other languages
Spanish (es)
Inventor
Maxime Gowen
Larry J Suvan
John Fox
George B Stroup
Edward F Nemeth
Original Assignee
Smithkline Beecham Corp
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Nps Pharma Inc filed Critical Smithkline Beecham Corp
Publication of CO5180628A1 publication Critical patent/CO5180628A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para tratar una enfermedad o un trastorno caracterizados por homeostasis ósea o mineral anormal, que comprende administrar a un sujeto que necesite dicho tratamiento una cantidad efectiva de un compuesto calciolítico conjuntamente con una cantidad efectiva de un agente anti-resorción.Un método según la reivindicación 1, en el que el compuesto calciolítico se selecciona del grupo constituido por:hidrocloruro de N-[(2R-hidroxi-3-[(3-cIoro-2-ciano)fenoxi-propil]-1,1-dimetil-2-(2-naftil)-etil-amina;hidrocloruro de N-[(2R-hidroxi-3-[(3-cloro-2-ciano)fenoxi-propil]-1,1-dimetil-2-( 4-metoxifenil)etil-amina;hidrocloruro de N-[(2R-hidroxi-3-[(2,3-dicloro)fenoxi-propil]- 1,1-dimetil-2-(4-metoxifenil)etil-amina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)suIfoniI]amino]fenoxi]propiI]-1,1-dimetil-2-(6-(1,2,3,4-tetrahidronaftil)etilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)suIfonil]amino]fenoxi]propiI]-1,1-dimetil-2-(benzotien-3-il)-etilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)suIfoniI]amino]fenoxi]propiI]-1,1-dimetil-2-(benzotien-2-il)-etilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifenil)suIfonil]amino]fenoxi]propil]-1,1-dimetiI-2 (decahidronaftalen-2-iI)etilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)sul- fonil]amino]fenoxi]propil]-1,1-dimetil-4-fenilbutilamina;N-[(R)-2-hidroxi-3-[2-ciano-4-[N-metil-N-[3-carboxifeniI)sul- fonil]amino]fenoxi]propiI]-1,1-dimetil-4-(2-metoxifenil)butila-mina;N-[2R-hidroxi-3-[[2-ciano-4-[N-metiI-N-[4-etilcarboxifeniI]-sulfoniI]amino]fenoxi]propil]-1,1-dimetil-2-(2-naftil)etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[N-metil-N-[3-metiIcarboxime-toxifeniI]suIfonil]-amino]fenoxi]propil]-1,1-dimetil-2-(2-naftil)etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsuIfonil]-N-[[[1-[2-[6-metil]amino]piridiI]etiI]amino]-fenoxi]propil]-1,1-dimetil-2-[2-naftil]etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsulfonil]-N-[[[1-[2-[6-metil]amino]piridil]etil]amino]-fenoxi]propil]-1,1-dimetil-2-(1,2,3,4-tetrahidronaft-6-il)etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsuIfonil]-N-[[[1-[2-[6-metiI]amino]piridil]etiI]amino]-fenoxi]propil]-1,1-dimetil-2-(benzotien-3-il)-etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsulfoniI]-N-[[[1-[2-[6-metil]amino]piridil]etil]amino]-fenoxi]propil]-1,1-dimetil-2-(benzotien-2-il)-etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsulfonil]-N-[[[1-[2-[6-metiI]amino]-piridil]etiI]amino]-fenoxi]propil]-1,1-dimetil-2-(decahidronaftalen-2-il)etilamina;N-[2R-hidroxi-3-[[2-ciano-4-[[N-metilsulfonil]-N-[[[1-[2-[6-metil]amino]piridil]etil]amino]-fenoxi]propil]-1,1-dimetil-4-(2-metoxifenil)butilamina; ....A method for treating a disease or disorder characterized by abnormal bone or mineral homeostasis, which comprises administering to an individual in need of such treatment an effective amount of a calciolytic compound together with an effective amount of an anti-resorption agent. A method according to claim 1, wherein the calciolytic compound is selected from the group consisting of: N - [(2R-hydroxy-3 - [(3-cyoro-2-cyano) phenoxy-propyl] -1,1-dimethyl-2 hydrochloride - (2-Naphthyl) -ethyl-amine; N - [(2R-hydroxy-3 - [(3-chloro-2-cyano) phenoxy-propyl] -1,1-dimethyl-2- (4-methoxyphenyl) hydrochloride ) ethyl-amine; N - [(2R-hydroxy-3 - [(2,3-dichloro) phenoxy-propyl] -1,1-dimethyl-2- (4-methoxyphenyl) ethyl-amine hydrochloride; N- [ (R) -2-hydroxy-3- [2-cyano-4- [N-methyl-N- [3-carboxyphenyl) suIfoniI] amino] phenoxy] propiI] -1,1-dimethyl-2- (6- ( 1,2,3,4-tetrahydronaphthyl) ethylamine; N - [(R) -2-hydroxy-3- [2-cyano-4- [N-methyl-N- [3-carboxyphenyl) suIfonyl] amino] phenoxy] propiI] -1,1-dimethyl-2- (benzothien-3-yl) -ethylamine; N - [( R) -2-hydroxy-3- [2-cyano-4- [N-methyl-N- [3-carboxyphenyl) suIfoniI] amino] phenoxy] propiI] -1,1-dimethyl-2- (benzothien-2- il) -ethylamine; N - [(R) -2-hydroxy-3- [2-cyano-4- [N-methyl-N- [3-carboxyphenyl) suIfonyl] amino] phenoxy] propyl] -1,1- dimetiI-2 (decahydronaphthalen-2-iI) ethylamine; N - [(R) -2-hydroxy-3- [2-cyano-4- [N-methyl-N- [3-carboxyphenyl) sulphonyl] amino] phenoxy] propyl] -1,1-dimethyl-4-phenylbutylamine; N - [(R) -2-hydroxy-3- [2-cyano-4- [N-methyl-N- [3-carboxyphenyl) sulphonyl] ] amino] phenoxy] propiI] -1,1-dimethyl-4- (2-methoxyphenyl) butylamine; N- [2R-hydroxy-3 - [[2-cyano-4- [N-methy-N- [ 4-ethylcarboxyphenyl] -sulfoniI] amino] phenoxy] propyl] -1,1-dimethyl-2- (2-naphthyl) ethylamine; N- [2R-hydroxy-3 - [[2-cyano-4- [N-methyl -N- [3-Methylcarboxymethoxyphenyl] suIfonyl] -amino] phenoxy] propyl] -1,1-dimethyl-2- (2-naphthyl) ethylamine; N- [2R-hydroxy-3 - [[2-cyano- 4 - [[N-MethylsuIfonyl] -N - [[[[1- [2- [6-methyl] amino] pyridiI] etiI] amino] -phenoxy] propyl] -1,1-dimethyl-2- [2-naphthyl ] ethylamine; N- [2R-hydroxy-3 - [[2-cyano-4 - [[N-methylsulfonyl] -N - [[[1- [2- [6-methyl] amino] pyridyl] ethyl] amino] -fen oxy] propyl] -1,1-dimethyl-2- (1,2,3,4-tetrahydronaft-6-yl) ethylamine; N- [2R-hydroxy-3 - [[2-cyano-4 - [[N -methylsuIfonyl] -N - [[[1- [2- [6-methy] amino] pyridyl] etiI] amino] -phenoxy] propyl] -1,1-dimethyl-2- (benzothien-3-yl) -ethylamine ; N- [2R-hydroxy-3 - [[2-cyano-4 - [[N-methylsulfoniI] -N - [[[1- [2- [6-methyl] amino] pyridyl] ethyl] amino] -phenoxy ] propyl] -1,1-dimethyl-2- (benzothien-2-yl) -ethylamine; N- [2R-hydroxy-3 - [[2-cyano-4 - [[N-methylsulfonyl] -N - [[ [1- [2- [6-Methy] amino] -pyridyl] eti] amino] -phenoxy] propyl] -1,1-dimethyl-2- (decahydronaphthalen-2-yl) ethylamine; N- [2R-hydroxy- 3 - [[2-cyano-4 - [[N-methylsulfonyl] -N - [[[1- [2- [6-methyl] amino] pyridyl] ethyl] amino] -phenoxy] propyl] -1,1- dimethyl-4- (2-methoxyphenyl) butylamine; ....

CO00056902A 1999-07-31 2000-07-28 CALCIOLITIC COMPOUNDS CO5180628A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14677899P 1999-07-31 1999-07-31

Publications (1)

Publication Number Publication Date
CO5180628A1 true CO5180628A1 (en) 2002-07-30

Family

ID=22518969

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00056902A CO5180628A1 (en) 1999-07-31 2000-07-28 CALCIOLITIC COMPOUNDS

Country Status (21)

Country Link
EP (1) EP1200076A4 (en)
JP (1) JP2003505502A (en)
KR (1) KR20020016928A (en)
CN (1) CN1367687A (en)
AU (1) AU764716B2 (en)
BR (1) BR0012921A (en)
CA (1) CA2380081A1 (en)
CO (1) CO5180628A1 (en)
CZ (1) CZ2002360A3 (en)
EC (1) ECSP003590A (en)
HK (1) HK1046238A1 (en)
HU (1) HUP0202167A3 (en)
IL (1) IL147875A0 (en)
MX (1) MXPA02001204A (en)
NO (1) NO20020466L (en)
PE (1) PE20010459A1 (en)
PL (1) PL353318A1 (en)
TR (1) TR200200278T2 (en)
UY (1) UY26265A1 (en)
WO (1) WO2001008673A1 (en)
ZA (1) ZA200200784B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
TW200845956A (en) * 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN108420814A (en) * 2017-02-15 2018-08-21 四川大学 A kind of NPS-2143 is used for the new application of antibacterial
CN116173187B (en) * 2023-03-14 2024-05-10 哈尔滨医科大学 Application of calcitonin in preparation of medicine for preventing and treating restenosis in stent, medicine coating stent and preparation method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726659B2 (en) * 1996-04-09 2000-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
AR018177A1 (en) * 1998-04-08 2001-10-31 Smithkline Beecham Corp CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR014975A1 (en) * 1998-04-08 2001-04-11 Nps Pharma Inc CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Also Published As

Publication number Publication date
AU764716B2 (en) 2003-08-28
ECSP003590A (en) 2002-02-25
PL353318A1 (en) 2003-11-17
NO20020466L (en) 2002-03-20
CA2380081A1 (en) 2001-02-08
JP2003505502A (en) 2003-02-12
BR0012921A (en) 2002-06-18
WO2001008673A1 (en) 2001-02-08
CZ2002360A3 (en) 2002-10-16
MXPA02001204A (en) 2004-05-21
IL147875A0 (en) 2002-08-14
EP1200076A4 (en) 2005-02-09
ZA200200784B (en) 2003-01-29
KR20020016928A (en) 2002-03-06
CN1367687A (en) 2002-09-04
HK1046238A1 (en) 2003-01-03
TR200200278T2 (en) 2002-06-21
NO20020466D0 (en) 2002-01-29
UY26265A1 (en) 2001-03-16
HUP0202167A3 (en) 2006-07-28
PE20010459A1 (en) 2001-06-11
AU6504100A (en) 2001-02-19
EP1200076A1 (en) 2002-05-02
HUP0202167A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
CO5180628A1 (en) CALCIOLITIC COMPOUNDS
Schick et al. The role of endonasal surgery in the management of frontoethmoidal osteomas.
KR960702846A (en) PEPTIDE INHBITORS OF UROKINASE RECEPTOR ACTIVITY
BRPI0109131B8 (en) dna, expression vector comprising the same, modified porcine factor viii, its production process and therapeutic composition comprising the same
ATE365720T1 (en) AGONISTS OF BETA-ADRENORECEPTORS
BR0312697A (en) Heterocyclically substituted benzoylureas, process for their preparation and application as a medicine
ES2162615T3 (en) METHOD TO TREAT OR PREVENT TYPE 1 DIABETES THROUGH ORAL INSULIN ADMINISTRATION.
FI963278A (en) Substance that improves platelet production
RU98123834A (en) METHODS AND COMPOSITIONS USED TO INHIBIT αvβ5-MEDIATED ANGI GENESIS
NZ592801A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CO5670327A2 (en) PROCEDURE FOR THE TREATMENT OF DEPRESSION AND ANXIETY DISORDERS THROUGH COMBINATION THERAPY
UY25713A1 (en) METHOD FOR TREATING DIABETES USING AN AP2 INHIBITOR AND COMBINATION.
CO5680411A2 (en) COMPOUNDS OF 1-PHENYL-2-DIMETHYLAMINE-METHYL-CYCLHEXAN, FOR THE THERAPY OF DEPRESSIVE SYMPTOMATOLOGY, PAIN AND INCONTINENCE
BRPI0211635B8 (en) cyclohexyl sulfone compound, its use, and pharmaceutical composition
FR2581382B1 (en) N- (QUINOLYL) GLYCINAMIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION AS PSYCHOTROPES
FI851752A0 (en) 2-AMINO-3-ETHOXICARBONYLAMINO-6 - (P-FLUORBENZYLAMINO) PYRIDING LUCONATES AND PHARMACEUTICAL PRODUCTS SOM INNEHAOLLER DETTA AEMNE.
Yu et al. Changes in serum FSH, LH and ovarian follicular growth during electroacupuncture for induction of ovulation
ES2066913T3 (en) CHROMAN DERIVATIVES.
SE9702066L (en) Fresh salt
Breusch et al. Significance of jet lavage for in vitro and in vivo cement penetration
Kehrl et al. Dexpanthenol nasal spray as an effective therapeutic principle for treatment of rhinitis sicca anterior
ATE63811T1 (en) USE OF TRANS-4-((2-AMINO-3,5-DIBROMOBENZYL)-AMINO>CYCLOHEXANOL.
MX9702037A (en) A method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs.
AR127533A1 (en) SARS-CoV-2 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
AR040690A1 (en) USE OF A SPECIFIC CYCLIC AMINE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS TO TREAT OR PREVENT CARDIAC INSUFFICIENCY

Legal Events

Date Code Title Description
FC Application refused